Equity Overview
Price & Market Data
Price: $8.05
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $42,581,884
Daily Volume: 0
Performance Metrics
1 Week: 0.12%
1 Month: -26.21%
3 Months: 48.20%
6 Months: 78.13%
1 Year: 136.8%
YTD: 46.66%
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.